TEMPORAL CHANGES IN THE GASTROINTESTINAL RISK PROFILE OF PATIENTS RECEIVING LOW-DOSE ACETYLSALICYLIC ACID FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS

(1) Spanish Centre for Pharmacoepidemiologic Research (CEIFE)

(2) AstraZeneca R&D



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS III session at UEG Week 2013

This item can be cited as: United European Gastroenterology Journal; 2013: 1 (Supplement 1) A570